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Abstract. Childhood neuroblastoma is one of the most 
common types of extra-cranial cancer affecting children with 
a clinical spectrum ranging from spontaneous regression to 
malignant and fatal progression. In order to improve the clin-
ical outcomes of children with high-risk neuroblastoma, it is 
crucial to understand the tumorigenic mechanisms that govern 
its malignant behaviors. MYCN proto-oncogene, bHLH tran-
scription factor (MYCN) amplification has been implicated in 
the malignant, treatment-evasive nature of aggressive, high-
risk neuroblastoma. In this study, we used a SILAC approach to 
compare the proteomic signatures of MYCN-amplified IMR-32 
and non-MYCN-amplified SK-N-SH human neuroblastoma 
cells. Tumorigenic proteins, including fatty-acid binding 
protein 5 (FABP5), L1-cell adhesion molecule (L1-CAM), bacu-
loviral IAP repeat containing 5 [BIRC5 (survivin)] and high 
mobility group protein A1 (HMGA1) were found to be signifi-
cantly upregulated in the IMR-32 compared to the SK-N-SH 
cells and mapped to highly tumorigenic pathways including, 
MYC, MYCN, microtubule associated protein Tau (MAPT), 
E2F transcription factor 1 (E2F1), sterol regulatory element 
binding transcription factor 1 or 2 (SREBF1/2), hypoxia-
inducible factor 1α (HIF-1α), Sp1 transcription factor (SP1) 
and amyloid precursor protein (APP). The transcriptional 
knockdown (KD) of MYCN, HMGA1, FABP5 and L1-CAM 
significantly abrogated the proliferation of the IMR-32 cells at 
48 h post transfection. The early apoptotic rates were signifi-
cantly higher in the IMR-32 cells in which FABP5 and MYCN 
were knocked down, whereas cellular migration was signifi-
cantly abrogated with FABP5 and HMGA1 KD compared 
to the controls. Of note, L1-CAM, HMGA1 and FABP5 KD 
concomitantly downregulated MYCN protein expression and 
MYCN KD concomitantly downregulated L1-CAM, HMGA1 
and FABP5 protein expression, while survivin protein expres-
sion was significantly downregulated by MYCN, HMGA1 and 
FABP5 KD. In addition, combined L1-CAM and FABP5 KD 
led to the concomitant downregulation of HMGA1 protein 
expression. On the whole, our data indicate that this inter-play 
between MYCN and the highly tumorigenic proteins which 
are upregulated in the malignant IMR-32 cells may be fueling 
their aggressive behavior, thereby signifying the importance 
of combination, multi-modality targeted therapy to eradicate 
this deadly childhood cancer.
Introduction
Neuroblastoma is a malignancy caused by the hyperplasia of 
naive neural crest cells (1). It is the most common solid tumor 
affecting children <5 years of age, and the third most common 
cause of pediatric cancer-related mortality (2), accounting 
for 7% of childhood malignancies and 15% of childhood 
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cancer-related mortalities (3). The disease is known for its 
broad range of clinical behavior and variable responses to 
treatment (4). This clinical heterogeneity is elucidated by the 
fact that some neuroblastomas can spontaneously regress or 
differentiate into a benign form, ganglioneuroma, while others 
are not responsive to current therapies (5). Even though the 
prognosis for children with neuroblastoma is generally good, 
the survival rates for children with high-risk neuroblastomas 
are still poor, despite advanced therapeutic strategies (6).
Several transcription factors have been shown to be 
involved in the pathogenesis of neuroblastoma by enhancing 
cancer cell proliferation (7). MYCN proto-oncogene, bHLH 
transcription factor (MYCN), one of these transcription 
factors, is a phosphoprotein in the MYC family of tran-
scription factors, encoded by the MYCN oncogene (7). The 
amplification of MYCN is one of the first most important 
genetic signatures of neuroblastoma (8). Patients with neuro-
blastoma carrying a MYCN amplification are classified in 
the high-risk group, and their 5-year overall survival rate 
following diagnosis does not exceed 50% (9). An amplifica-
tion leading to the aberrant expression of MYCN has been 
associated with tumor aggressiveness, resistance to chemo-
therapy and the inability to differentiate (10). In fact, MYCN 
amplification confers cell resistance to apoptosis induced by 
the tumor necrosis factor-related apoptosis-inducing ligand 
system (11), whereas MYCN silencing promotes proliferation 
arrest, differentiation and the apoptosis of human neuroblas-
toma cells (12).
In the present study, we conducted a pilot proteomics 
analysis to compare the proteomic signature of the MYCN-
amplified IMR-32 cells to that of the non-MYCN-amplified 
SK-N-SH human neuroblastoma cells using stable isotope 
labeling by amino acids in cell culture (SILAC) strategy (13). 
Of the differentially expressed proteins (based on expression 
value and fold change) between the IMR-32 and SK-N-SH 
cells, we were particularly interested in proteins upregulated 
in the IMR-32 compared to the SK-N-SH cells that mapped 
to upstream regulators [MYCN, MYC, hypoxia-inducible 
factor-1α (HIF-1α), E2F transcription factor 1 (E2F1), 
Sp1 transcription factor (SP1), KIT ligand (KITLG), inter-
leukin 3 (IL3), amyloid precursor protein (APP), insulin 
receptor (INSR) and sterol regulatory element binding tran-
scription factor 1 or 2 (SREBF1/2)] predicted by Ingenuity 
Pathway Analysis (IPA; Ingenuity Systems, Inc., Redwood City, 
CA, USA; 2000-2014) to be activated in the IMR-32 cells. 
These included: L1 cell adhesion molecule (L1-CAM); high 
mobility group protein A1 (HMGA1); fatty acid-binding 
protein 5 (FABP5); and baculoviral IAP repeat containing 5 
[BIRC5 (survivin)].
In the present study, we aimed to determine the interac-
tion between the above-mentioned molecules and MYCN 
in the IMR-32 cells and the effect of transcriptional 
knockdown (KD) of these targets on cellular proliferation, 
migration and apoptosis. We also wished to determine the 
cellular bio-function after single-target versus double-target 
transcriptional KD of the said proteins and whether an added 
effect would be observed. In addition, we were interested in 
examining whether a crosstalk exists between these proteins 
as determined by differential protein expression levels of one 
target after transcriptional KD of each of the other targets.
Materials and methods
Reagents and human cell lines. The IMR-32 (MYCN-
amplified) and SK-N-SH (non-MYCN-amplified) cells are 
human neuroblastoma/neuroepthelioma cell lines purchased 
from the American Type Culture Collection (ATCC, Manassas, 
VA, USA) where routine STR testing was conducted and the 
cells were confirmed to derive from human species. In addition, 
the cells were routinely tested for mycoplasma, aerobic and 
anaerobic bacteria, and human pathogenic viruses including 
human immunodeficiency virus (HIV), hepatitis B (HepB), 
human papilloma virus (HPV), Epstein-Barr virus (EBV) 
and cytomegalovirus (CMV), all of which our cells tested 
negative for and were used within 6 months of purchase from 
ATCC. The cells were cultured in minimal essential Eagle's 
medium (EMEM; cat. no. M2279) supplemented with 2 mM 
L-glutamine (cat. no. 7513; Sigma, St. Louis, MO, USA), 
2% penicillin streptomycin (cat. no. P4333SIGMA), 1 mM 
sodium pyruvate (cat. no. S8636), 2% non-essential amino acids 
(cat. no. M7145) and 10% fetal bovine serum (cat. no. F9665) 
(all from Sigma). The cells were cultured to 80% confluence in 
T25 flasks at 5% CO2 and 37˚C. The medium was replenished 
every 48 h. After 8 days, the cells covering 80% of the flask 
were collected and transferred into a 15 ml falcon tube to be 
centrifuged at 200 x g for 10 min at 4˚C. The old medium 
was discarded and the cells were re-suspended in 10 ml of 
fresh medium and transferred into a T75 flask. The cells 
harvested from T75 flasks were frozen in Corning® Cryotubes 
(Corning Inc., New York, NY, USA) using 50% fetal bovine 
serum (FBS), 40% EMEM and 10% DMSO (D2650; Sigma) 
to a final volume of 1 ml. The cryotubes were frozen first at 
-80˚C for 24 h in isopropanol to provide a gradual decrease in 
temperature. They were then transferred to liquid nitrogen for 
long term storage.
SILAC proteomics sample preparation. The IMR-32 and 
SK-N-SH neuroblastoma cells were grown in the standard 
culture conditions until they reached confluency after which 
they were washed 6 times with serum-free medium and then 
cultured in serum-free medium supplemented with ‘heavy’ 
isotopes where arginine and lysine were replaced with 13C6-Arg 
and 13C6, 15N2-Lys (Cambridge Isotopes, Andover, MA, USA) for 
6 doublings to ensure incorporation of the isotopes into the entire 
cellular population. After 6 doublings, the cells were collected, 
lysed, quantified and mixed together into one SuperSILAC 
mastermix cocktail and saved at -80˚C. The cells were then 
cultured in serum-free growth medium supplemented with 
‘light’ isotopes where arginine and lysine were replaced with 
12C6-Arg and 12C6, 14N2-Lys until they reached ~80% confluency. 
The cells were lysed at that point and quantified, and a 
‘spike-in’ strategy used to spike-in the ‘heavy’ labeled cellular 
lysates into the ‘light’ labeled cellular lysates at a 1:1 ratio. 
Approximately 100 µg of total protein mixture (50:50 µg of 
cell lysate:SuperSILAC cocktail) was loaded onto a 4-12% 
polyacrylamide gel and electrophoresed until the proteins were 
well-separated. The gel was fixed and stained with Commassie 
Blue (Bio-Rad, Hercules, CA, USA) then de-stained overnight in 
H2O at 4˚C. The gels were then sliced into ~35-40 bands which 
underwent in-gel digestion with trypsin (Promega, Madison, 
WI, USA) using a previously documented protocol (14) and 
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the resultant peptides derived from each band were dried by 
vacuum centrifugation (240 x g) at room temperature, and 
re-suspended in 6 µl of 0.1% TFA for analysis by mass spec-
trometry and proteomics analysis as previously described (15).
Mass spectrometry analysis and protein identification and 
quantification. The methods used to conduct the mass spec-
trometry and protein identification and quantification were 
exactly as described in the study by Formolo et al (15).
IPA, STRING protein networks and Enrichr analysis tool. 
Ingenuity Systems, Inc. 2000-2014 (content version, 18030641; 
release date, December 6, 2013) was used to derive the target 
molecules within the data set, upstream regulators, molecule 
type, predicted activation status with activation z-score and 
P-values of the proteins differentially expressed between the 
IMR-32 and SK-N-SH cells based on expression of and number 
of peptides detected per protein, where anything >2-fold 
is considered upregulated and anything below 0.5-fold is 
considered downregulated. The Enrichr (16,17) tool was used 
to annotate the differentially expressed proteins between the 
IMR-32 and SK-N-SH cells. Proteins in the network that were 
differentially expressed in the IMR-32 cells were mapped to 
the top diseases and bio-functions. Differential expression was 
determined as either upregulated (>2-fold) or downregulated 
(<0.5-fold) in the IMR-32 compared to the SK-N-SH cells. 
The STRING protein network tool was used to determine any 
interactions (experimentally determined, from curated data-
bases and text-mining) between our proteins of interest.
Protein extraction for validation by western blot analysis. 
The IMR32 and SK-N-SH cells were collected into 15-ml 
falcon tubes and centrifuged at 200 x g for 10 min at 4˚C. The 
medium was discarded and the pellet was washed twice with 
Dulbecco's phosphate-buffered saline (PBS; D8537; Sigma). 
PBS was then discarded and the cells were incubated on ice 
for 40 min with 120 µl of lysis buffer (for a confluent T75 flaks) 
composed of 50 Mm tris-HCl (pH 7.5), 1 mM EDTA, 250 mM 
NaCl, 50 mM NaF, 0.1 mM Na3VO4, 0.5% Titron X-100 
and 1X protease inhibitor cocktail (cat no. 11697498001; 
Roche, Indianapolis, IN, USA). The lysates were transferred 
to Eppendorf tubes where they were centrifuged at 4˚C for 
20 min at 8,000 x g to eliminate cellular debris. The super-
natants were then transferred to new Eppendorf tubes where 
they were mixed with 60 µl of the 3X sample buffer (0.5 M 
tris-HCl, glycerol, 10% SDS, β-mercaptoethanol and 0.05% 
bromophenol blue) in preparation for western blot analysis.
Western blot analysis. Protein expression was confirmed by 
western blot analysis as previously described (18). Briefly, 
For L1-CAM, glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) and HMGA1 detection, a 10% polyacrylamide 
(cat. no. 161-0156; Bio-Rad) gel was used; however, for FABP5 
and MYCN detection a 12% polyacrylamide gel was used. A 
5% stacking gel was used to form the wells. The extracted 
proteins were separated on gels using a current of 150 mV. 
Proteins were then transferred to a PVDF membrane (cat. 
no. 1620177; Bio-Rad) for 90 min at 100 mV which was then 
blocked using 5% BSA (cat. no. A2153-100G; Sigma) diluted 
in 1X TBS with 1% Tween-20 (cat. no. 9005-64-5).
The blots were incubated with rabbit monoclonal L1-CAM 
(cat. no. ab20148), HMGA1 (cat. no. ab129153), FABP5 (cat. 
no. ab84028), survivin (cat. no. ab469) (all from Abcam, 
Cambridge MA, USA) and MYCN antibodies (cat. no. 9405; 
Cell Signaling Technology, Danvers, MA, USA) and with 
mouse monoclonal GAPDH antibody (cat. no. ab9484) 
(Abcam) overnight (all diluted 1:1,000 in TBS-T +5% BSA 
blocking solution). The blots were washed 5 times for 5 min 
with TBST and then incubated with secondary antibodies 
[goat anti-rabbit (cat. no. 170-5046) or goat anti-mouse (cat. 
no. 170-5047) HRP-conjugated secondary antibodies from 
Bio-Rad] for 1 h. After washing, the blots were incubated with 
Clarity Western ECL substrate (cat. no. 1705060; Bio-Rad) for 
3 min and imaged using the Bio-Rad© ChemiDoc system and 
analyzed using ImageLab® software. The bands obtained were 
normalized to GAPDH.
Transcriptional KD of target proteins. The 4 siRNA oligo-
nucleotides for L1-CAM (Hs L1-CAM_4 SI00009296, Hs 
L1-CAM_3 SI00009289, Hs L1-CAM_2 SI00009282 and Hs 
L1-CAM_1 SI00009275; Qiagen, Valencia, CA, USA), HMGA1 
(D-004597-01 HMGA1, D-004597-02 HMGA1, D-004597-03 
HMGA1 and D-004597-18 HMGA1; Dharmacon, Lafayette, 
CO, USA), MYCN (Hs_MYCN_7 SI03113670, Hs_MYCN_6 
SI03087518, Hs_MYCN_5 SI03078222 and Hs_MYCN_3 
SI00076300; Qiagen) and FABP5 (Hs_FABP5_10 SI04277553, 
Hs_FABP5_9 SI04210948, Hs_FABP5_8 SI04210941 and 
Hs_FABP5_5 SI03145835; Qiagen) were reconstituted in 
RNAase-free water to a final concentration of 10 µM. A total 
of 5x105 cells were seeded in each well of a 6-well plate in a 
final volume of 2 ml of antibiotics-free medium. The cells were 
transfected with the siRNA using the fast-forward Hiperfect 
transfection protocol following the manufacturer's instructions 
(cat. no. 301705; Qiagen). A final concentration of 100 nM of 
each siRNA was achieved by mixing 10 µl of the 10 µM siRNA 
with 10 µl of Hiperfect (cat. no. 301705; Qiagen) and 370 µl of 
OptiMEM (cat. no. 31985-062; Life Technologies, Carlsbad, 
CA, USA). The mixture was incubated at room temperature for 
20 min, and added in a drop-wise manner to the corresponding 
wells. The negative control was prepared by treating the cells 
with 90 µl of OptiMEM and 10 µl of Hiperfect. The cells were 
then incubated with the siRNAs for 48 h, lysed and processed 
for western blot analysis.
WST-1 cell proliferation assay. In order to examine the effects 
of KD on cellular proliferation, a WST-1 cell proliferation assay 
was conducted. A total of 5x104 cells were cultured in each 
well of a 96-well plate in a final volume of 100 µl. Duplicates 
of each condition were prepared. The cells were transfected 
with L1-CAM, HMGA1, MYCN, FABP5 or scrambled siRNAs 
in a final concentration of 100 nM. The cells were incubated 
in 100 µl growth medium for 24, 48 and 72 h and treated with 
10 µl of WST-1 reagent (cat. no. ab155902; Abcam) per well 
prior to reading. The absorbance was detected after 3 h using 
an Epoch™ Microplate Spectrophotometer at 450 nm (BioTek, 
Winooski, VT, USA).
Annexin V-FITC/propidium iodide (PI) apoptosis detec-
tion assay. The IMR32 cells were cultured in a 6-well plate 
(5x105 cells/well), and transfected with the various siRNA 
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constructs as described above. Negative control cells were 
either unlabeled/untreated or Annexin V-FITC- and PI-labeled 
and untreated. Positive control cells were transfected 
with 100 nM siRNA of our target constructs and labeled 
with Annexin V-FITC and PI or Annexin V-FITC alone. 
The cells were then collected at 48 h using accutase (cat. 
no. A11105-01; Thermo Fisher Scientific, Waltham, MA, USA) 
and centrifuged at 200 x g for 5 min at 4˚C. They were then 
re-suspended in 500 µl of 1X binding buffer, treated with 5 µl 
of Annexin V-FITC or PI from Abcam (cat. no. ab14085) and 
incubated in the dark for 5 min prior to flow cytometric analysis 
using FACSCalibur flow cytometer (BD Biosciences, San Jose, 
CA, USA). Data were analyzed using IQuest Pro software 
(version 5.1) (BD Biosciences). IMR32 cells were identified 
by their forward-scatter (FSC) and side-scatter (SSC) charac-
teristics. Viable, early apoptotic, late apoptotic and dead cell 
populations were identified as Annexin V-/PI-, Annexin V+/PI-, 
Annexin V+/PI+ and Annexin V-/PI+, respectively. Cells stained 
with Annexin V-FITC or PI alone were used to adjust color 
compensation settings on flow cytometer. A minimum of 
20,000 cell events were recorded for each sample.
Wound healing migration assay. The IMR-32 cells were grown 
to ~70% confluency in triplicates of 12-well plates in standard 
culture medium and conditions. FABP5 or HMGA1 siRNA 
transfection was conducted as described above and after 24 h, 
the cells were scraped down the midline of the plate to resemble 
a ‘wound’. The cells which were scraped off were washed 2X 
with serum-free medium and fresh medium replenished and 
the cells were then imaged (0 h time-point) and cultured under 
standard growth culture conditions for 24 h. The cells were 
then imaged at several random fields down the scratched 
‘wound’ area and the area (µM2) of ‘wound-closure’ after 24 h 
in siRNA KD-compared to control siRNA-transfected cells 
was measured using AxioVision Systems software (Zeiss, 
Oberkochen, Germany). The average of the areas of multiple 
random fields was represented as a fold change compared to 
untransfected controls and graphed using Microsoft Excel 
software.
Statistical analysis. Experiments were conducted in triplicate, 
repeated 3 independent times and the means ± the standard 
error of the means (SEM) of all 3 experiments was calculated 
and plotted. A two-sided Student's t-test was used to deter-
mine statistically significant differences between groups. A 
one-way analysis of variance (ANOVA) test was used followed 
by a post hoc Fisher's least significant difference (LSD) test 
to determine the significance among the means of multiple 
groups obtained from ≥3 independent experiments. The 
means ± SEM of 3 or more experiments was derived and 
graphed using Microsoft Excel software. Statistical signifi-
cance was set at a P-value <0.05.
Results
Top networks, diseases and bio-functions to which overex-
pressed proteins in IMR-32 cells are mapped. We conducted 
preliminary proteomics analysis of the MYCN-amplified 
IMR-32 compared to the non-MYCN-amplified SK-N-SH 
human neuroblastoma cell lines using a highly quantitative 
SILAC methodology. The significant, differentially expressed 
proteins were then annotated using IPA in order to predict 
the upstream regulators of highly tumorigenic proteins in the 
IMR-32 compared to the SK-N-SH cells. The total numbers of 
differentially expressed proteins were found to be 875 out of 
4,960 proteins (either >2-fold upregulated or <0.5-fold down-
regulated) in the IMR-32 compared to the SK-N-SH cells. 
These proteins were affiliated with upstream regulators that 
IPA predicted to be activated in the IMR-32 compared to the 
SK-N-SH cells based on the molecules identified in our dataset 
(data not shown).
Table I lists the top diseases and disorders, molecular 
and cellular bio-functions, as well as physiological system 
development and function categories that proteins signifi-
cantly overexpressed in the IMR-32 cells are mapped to; the 
fold change cut-off was set at ≥2-fold. Renal and urological, 
neurological, hereditary and infectious diseases, as well as 
organismal injury and abnormalities, were among the top 
disease categories that the proteins were mapped to Table IA. 
RNA post-transcriptional modification, molecular transport, 
RNA trafficking, cellular compromise and gene expression 
were among the top molecular and cellular functions that 
the overexpressed proteins in the IMR-32 cells were mapped 
to Table IB. The physiological system development and 
function categories that proteins belonged to included tissue 
development, nervous system development and function, 
connective tissue development and function and embryonic 
development (Table IC).
Fold change and predicted activated up-stream regulators 
of proteins overexpressed in IMR-32 compared to SK-N-SH 
cells. IPA was used to predict the activation status of the 
upstream regulators of the differentially expressed proteins 
between the IMR-32 and SK-N-SH cells. Table II lists the top 
molecules and the fold change of upregulated proteins which 
included, CaM kinase like vesicle associated (CAMKV), tumor 
protein D52 (TPD52), argininosuccinate synthetase 1 (ASS1), 
FABP6, L1-CAM, FABP5, DNA polymerase γ, catalytic subunit 
(POLG), collapsin response mediator protein 1 (CRMP1), ribo-
nuclease H2 subunit B (RNASEH2B) and G protein subunit αO1 
(GNAO1). MYCN, hepatocyte nuclear factor 4α (HNF4A), 
microtubule associated protein Tau (MAPT), APP and E2F 
were predicted to be activated upstream regulators of the 
proteins in this dataset, as determined by IPA (based on the 
target molecules that were found to be >2-fold upregulated in 
the IMR-32 compared to the SK-N-SH cells). In addition to 
the top upstream regulators, Table III lists additional upstream 
regulators predicted to be activated or inhibited in the IMR-32 
compared to the SK-N-SH cells. Of note, is the activation of 
cancer-promoting, angiogenic and cancer stemness players, such 
as MYC, HIF-1α, eukaryotic translation initiation factor 4γ1 
(EIF4G1), IL3, angiopoietin 2 (ANGPT2) and SREBF in the 
IMR-32 cells. Molecules predicted to be inhibited in the IMR-32 
compared to the SK-N-SH cells included Aly/REF export factor 
(ALYREF), Ankyrin (ANK)2, autophagy related 7 (ATG7), 
coiled-coil domain containing 88A (CCDC88A), chromatin 
target of PRMT1 (CHTOP), cleavage and polyadenylation 
specific factor 1 (CPSF1), CPSF2 and CPSF3 among others, 
primarily involved in RNA post-transcriptional modification, 
molecular transport and RNA trafficking.
INTERNATIONAL JOURNAL OF ONCOLOGY  52:  787-803,  2018 791
Proteins overexpressed in the IMR-32 cells belong to 
tumorigenic pathways. The proteins overexpressed in the 
IMR-32 compared to the SK-N-SH cells that belonged to 
the upstream regulators predicted to be activated by IPA 
(SREBF1, SP1, SCAP, SREBF2, IL3, KITLG, FLI1, INSR, 
HIF-1α, MYC, EIF4E and ANGPT2 among others), mapped 
to signaling pathways that drive cancer stem cell mainte-
nance and propagation (Notch) (19), invasion and metastasis 
[Rac1/Pak1/p38/MMP-2 (20) and the leptin signaling 
pathway (21)], cancer malignancy [SREBP signaling (22) and 
the AGE/RAGE pathway (23)] and proliferation [AMPK path-
ways (24)]. Table IV lists the upstream regulators predicted to 
be activated by IPA, with adjusted P-values for the overexpres-
sion level in the IMR-32 cells and the pathways in which these 
regulators have been demonstrated to play pivotal roles.
IMR-32 cells significantly overexpress the tumorigenic 
proteins, HMGA1, L1-CAM, FABP5 and BIRC5. Of the 
highly tumorigenic proteins identified to be upregulated in the 
IMR-32 compared to the SK-N-SH cells, we decided to focus 
our investigation on L1-CAM, HMGA1, FABP5, BIRC5 and 
MYCN as they mapped to several of the activated upstream 
regulators, as predicted by IPA and due to their tumorigenic 
roles played in various types of cancer as elaborated below in 
the ‘Discussion’. Western blot analysis was used to determine 
the levels of HMGA1, FABP5, BIRC5 and L1-CAM, as well as 
MYCN protein expression between the IMR-32 and SK-N-SH 
cells. As expected, we found all these targets to be signifi-
cantly overexpressed in the IMR-32 compared to the SK-N-SH 
neuroblastoma cells. Fig. 1A is a representative demonstra-
tion of multiple western blotting experiments verifying the 
Table I. Functional annotation of proteins upregulated in the IMR-32 compared to the SK-N-SH human neuroblastoma cell lines.
A, Diseases and disorders
Name P-value No. of molecules
Infectious disease 2.02E-09-1.69E-02 135
Organismal injury and abnormalities 2.02E-09-1.89E-02 164
Renal and urological disease 4.93E-09-1.69E-02   70
Hereditary disorder 8.90e-07-1.89e-02   41
Neurological disease 8.90E-07-1.75E-02   98
B, Molecular and cellular functions
Name P-value No. of molecules
RNA post-transcriptional modification 2.54E-33-1.73E-02   75
Molecular transport 4.20E-11-1.73E-02   75
RNA trafficking 4.20E-11-1.97E-02   23
Cellular compromise 1.45E-10-1.90E-02   38
Gene expression 1.19E-07-1.07E-02 180
Associated network function Score
RNA post-transcriptional modification, molecular transport,  45
RNA trafficking
Gene expression, RNA damage and repair, RNA 45
post-translational modification
Cellular assembly and organization, cellular function and 40
maintenance, tissue development
Cellular movement, developmental disorder, hereditary disorder 38
Cellular compromise, cell cycle, cellular assembly and organization 38
C, Physiological system development and function
Name P-value No. of molecules
Tissue development 8.61E-06-1.57E-02 70
Nervous system development and function 6.52E-05-1.73E-02 75
Connective tissue development and function 7.68E-04-1.89E-02 55
Embryonic development 7.68E-04-1.73E-02 66
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upregulation of these targets, as indicated by the SILAC 
proteomics data. Densitometric analysis revealed a significant 
upregulation of the protein expression of L1-CAM (~1-fold 
overexpressed), MYCN (~7-fold overexpressed), HMGA1 
(~0.5-fold overexpressed), BIRC5 (~1-fold overexpressed) and 
FABP5 (~4-fold overexpressed) in the IMR-32 compared to 
the SK-N-SH cells (Fig. 1B).
Upregulated proteins in IMR-32 cells mapped to the highly 
tumorigenic MYCN pathway. The STRING protein network 
database was used to analyze the interactions (experimen-
tally determined and from curated databases) between the 
activated upstream regulators of the overexpressed proteins 
in the IMR-32 cells (HMGA1, L1-CAM, BIRC5, FABP5, 
MYC, INSR, SP1, HIF1A and SREBF1/2 among others) and 
MYCN (Fig. 2A). In addition, we used STRING protein 
network analysis to focus on the interactions between the acti-
vated upstream regulators, which our validated proteins (by 
western blot analysis; HMGA1, L1-CAM, FABP5 and BIRC5) 
mapped to Fig. 2B). Of particular interest, are the various 
hubs (proteins with multiple edges) identified, including INSR, 
SP1, HIF-1α, MYC, MYCN, HMGA1 and SREBF that show 
strong interactions (experimentally-determined, from curated 
databases and text-mining) with many other tumorigenic 
proteins (Fig. 2A). We further highlight the important inter-
actions (experimentally determined, from curated databases 
and text-mining) between our validated targets (by western 
blot analysis; HMGA1, BIRC5 and MYCN) and the activated 
upstream regulators, SP1, SREBF1, MYC, KITLG, IL3, INSR 
and HIF-1α (Fig. 2B). KEGG pathway analysis mapped the 
number of molecules to various pathways, most of which are 
known tumorigenic drivers, including PI3K/Akt, Ras, Rap1, 
Wnt, HIF-1α, transforming growth factor-β (TGF-β) and 
mammalian target of rapamycin (mTOR) and insulin signaling 
pathways (Table V). This intricate network of interplay 
between these highly tumorigenic proteins warrants further 
Figure 1. Verification of proteomics data. (A) Representative western blot images of L1-cell adhesion molecule (L1-CAM), MYCN proto-oncogene, bHLH 
transcription factor (MYCN), high mobility group protein A1 (HMGA1), survivin and fatty-acid binding protein 5 (FABP5) protein expression in the IMR-32 
compared to the SK-N-SH cells. (B) Densitometric analysis verified the proteomics data and revealed the significant overexpression of L1-CAM, MYCN, 
HMGA1, survivin and FABP5 in the IMR-32 compared to the SK-N-SH cells. Experiments were run in triplicate and repeated >3 times. Results represent the 
means ± SEM; *P<0.05 and **P<0.01.
Table II. Fold change of top 10 proteins upregulated in the 
IMR-32 versus the SK-N-SH human neuroblastoma cells.
Molecules Fold change
CAMKV 103.800
TPD52 39.976
ASS1 24.995
FABP5 18.000
POLG 16.726
L1-CAM 16.708
CRMP1 15.295
FABP6 15.268
RNASEH2B 15.250
GNAO1 14.943
Upstream P-value of Activation
regulator overlap predicted state
MYC 1.52E-18 Activated
HNF4A 2.15E-15
MAPT 7.36E-12
APP 1.10E-11
E2F 1.37E-11
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investigation, particularly in pre-clinical, animal models, 
whereby multiple targeting of more than one of these players 
may yield beneficial, antitumor effects and improve thera-
peutic outcomes.
Novel pathways link the MYCN-affected proteins in the 
IMR-32 cells to cancer malignancy. In addition to the 
above-mentioned pathways, when we combined only MYC, 
MYCN and our validated targets in the STRING protein 
network analysis (Fig. 3A), we found very strong interactions 
between MYC, MYCN, BIRC5 and HMGA1 with Aurora kinase 
(AURK)A/B, cyclin-dependent kinase 1 (CDK1), cell division 
cycle associated 8 (CDCA8) and INCENP. These players were 
mapped to cellular functions highly affiliated with mitosis and 
cellular division and proliferation (Table VI). Lastly, L1-CAM 
focused network analysis revealed its strong interaction with 
neural cell adhesion molecule 1 (NCAM1), neurocan (NCAN), 
ezrin (EZR), RDX, ANK1, ANK2, contactin 2 (CNTN2), neuro-
pilin 1 (NRP1), epidermal growth factor receptor (EGFR) and 
RAN binding protein 9 (RANBP9) (Fig. 3B), most of which 
drive angiogenic and migratory processes to fuel cellular inva-
sion, migration and metastatic spread.
Transcriptional KD experiments reveal interplay between 
tumorigenic proteins upregulated in IMR-32 cells. We then 
aimed to transcriptionally KD the protein expression of these 
molecules and determine the effects of this KD on cellular bio-
function. Additionally, we wished to determine whether the 
downregulation of one protein would affect the expression level 
of the other targets, thereby implicating a potential interplay 
between the proteins. Using transient siRNA transfection, we 
successfully downregulated the protein expression (Fig. 4A) of 
MYCN (~85%), HMGA1 (~60%), FABP5 (~60%) and L1-CAM 
(~80%) as determined by western blot analysis at 48 h after 
siRNA transfection (Fig. 4B). Of note, L1-CAM, HMGA1 and 
FABP5 transcriptional KD led to the significant concomitant 
downregulation of MYCN protein expression by ~80, 90 and 
75%, respectively (Fig. 5A). In addition, MYCN transcriptional 
Table III. Upstream regulators predicted to be either activated (in addition to the above top 5 upstream regulators), or inhibited 
in the IMR-32 compared to the SK-N-SH cells based on the statistically significant over- or underexpression of molecules within 
the IPA-derived dataset.
Predicted to be activated MYC, ESRRA, MYCN, INSR, HIST1H1T, HIST1H1A, HIF1A, EIF4E, EIF4G1, SREBF2, 
 ANGPT2, FLI1, IL3, SREBF1, SCAP, RUVBL1, SP1, CD40LG, EPAS1, KITLG, ADORA2A, 
 PGR, KAT5, PSEN1
Predicted to be inhibited ALYREF, ANK2, ATG7, CCDC88A, CHTOP, CPSF1, CPSF2, CPSF3, CSTF1, DDX39A, 
 DDX39B, DENR
Table IV. Functional annotation of upstream regulators of the overexpressed proteins in the IMR-32 cells and the signaling 
pathways they are affiliate witha.
 Adjusted
Pathways P-value Genes overexpressed
SREBP signaling_WP1982 8.04E-05 SREBF1, SP1, SCAP, SREBF2
Adipogenesis_WP236 4.00E-04 SREBF1, EPAS1, SP1, HIF1A
Hematopoietic stem cell differentiation 4.55E-04 IL3, KITLG, FLI1
AGE/RAGE pathway_WP2324 9.50E-04 SP1, INSR, HIF1A
SREBF and miR-33 in cholesterol and lipid homeostasis_WP2011 2.79E-03 SREBF1, SREBF2
Mitochondrial gene expression_WP391 3.11E-03 ESRRA, SP1
Nuclear receptors_WP170 9.47E-03 ESRRA, PGR
Integrated pancreatic cancer pathway_WP2377 1.20E-02 IL3, SP1, MYC
Differentiation pathway_WP2848 1.20E-02 IL3, KITLG
Translation factors_WP107 1.20E-02 EIF4E, EIF4G1
Notch signaling pathway_WP61 1.67E-02 MYC, HIF1A
Rac1/Pak1/p38/MMP-2 pathway_WP3303 1.84E-02 ANPGPT2, MYC
AMPK signaling_ WP1403 1.85E-02 SREBF1, INSR
Leptin signaling pathway_WP2034 2.08E-02 SP1, EIF4E
Androgen receptor signaling pathway_WP138 2.78E-02 KAT5, SP1
DNA damage response (only ATM dependent)_WP710 4.08E-02 MYC, INSR
miR-148/miR-31/FIH1/HIF1? - Notch signaling in glioblastoma_WP3593 5.00E-02 HIF1A
aAs derived from Enrichr using the IPA-predicted activated up-stream regulators dataset.
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KD led to the significant concomitant downregulation of 
L1-CAM, HMGA1 and FABP5 protein expression by ~77, 75 
and 70, respectively (Fig. 5B). Moreover, the combined tran-
scriptional KD of L1-CAM and FABP5 led to the significant 
concomitant downregulation of HMGA1 protein expression by 
~70% (Fig. 5C), while survivin protein expression was abro-
gated following the transcriptional KD of MYCN, HMGA1 
and FABP5 (Fig. 5D). This interplay between these tumori-
genic proteins is extremely interesting and warrants further 
investigation into the mechanisms utilized by this network to 
drive cancerous progression and malignant, treatment-evasive 
recurrence in high-risk, MYCN-amplified pediatric neuroblas-
tomas.
Transcriptional KD of tumorigenic proteins inhibits the 
proliferation and migration of IMR-32 cells. To determine 
the cellular bio-functional effects of the transcriptional 
downregulation of our protein targets, we examined the rate 
of proliferation of the IMR-32 cells over 5 days following the 
transcriptional KD of these tumorigenic proteins. We observed 
Figure 2. Tumorigenic proteins significantly upregulated in the IMR-32 cells mapped to the MYCN proto-oncogene, bHLH transcription factor (MYCN) 
pathway. (A) STRING pathway analysis revealed interactions between molecules of activated upstream regulators in IMR-32 cells as predicted by IPA. 
Of importance are the various proteins with hubs (multiple edges, red circles), including Sp1 transcription factor (SP1), MYC, MYCN, hypoxia-inducible 
factor-1α (HIF-1α), high mobility group protein A1 (HMGA1), INSR, KIT ligand (KITLG), sterol regulatory element binding transcription factor 2 (SREBF2) 
and SREBF1. (B) STRING pathway analysis also focused on the strong interactions between the activated upstream regulators which HMGA1, MYCN and 
BIRC5 mapped to. Of particular interest are the hubs, including MYCN, MYC, SP1, HIF-1α, SREBF1, BIRC5, HMGA1 and INSR that affiliated with one or 
more of our validated targets.
Table V. Common tumorigenic pathways that MYCN, BIRC5 and the activated upstream regulators mapped to.
   False
Pathway Pathway Observed discovery Matching proteins in
ID no. description gene count rate your network (labels)
4151 PI3K-Akt signaling pathway 6 1.26E-05 ANGPT2, EIF4E, IL3, INSR, KITLG, MYC
5202 Transcriptional misregulation in cancer 5 1.26E-05 FLI1, IL3, MYC, MYCN, SP1
4066 HIF-1 signaling pathway 4 7.58E-05 ANGPT2, EIF4E, HIF1A, INSR
5200 Pathways in cancer 5 5.02E-03 BIRC5, HIF1A, KITLG, MYC, EPAS1
4910 Insulin signaling pathway 3 6.48E-03 EIF4E, INSR, SREBF1
4015 Rap1 signaling pathway 4 1.95E-02 ADORA2A, ANGPT2, INSR, KITLG
4014 Ras signaling pathway 3 2.05E-02 ANGPT2, INSR, KITLG
4310 Wnt signaling pathway 3 1.84E-02 MYC, PSEN1, RUVBL1
4150 mTOR signaling pathway 2 2.67E-02 EIF4E, HIF1A
5210 Colorectal cancer 2 2.67E-02 BIRC5, MYC
4350 TGF-β signaling pathway 2 4.08E-02 MYC, SP1
4640 Hematopoietic cell lineage 2 4.51E-02 IL3, KITLG
When we combined the predicted activated upstream regulators and MYCN in the STRING protein network analysis, the common pathways 
identified were highly tumorigenic, including PI3K-Akt, transcriptional misregulation in cancer, pathways in cancer, HIF-1, Wnt, Rap1, Ras, 
mTOR, TGF-β and insulin signaling pathways.
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Figure 3. Novel pathways link the MYCN proto-oncogene, bHLH transcription factor (MYCN)-affected proteins in IMR-32 cells to cancer malignancy. 
(A) STRING pathway analysis revealed very strong interactions between MYCN, BIRC5, high mobility group protein A1 (HMGA1) and the cellular mitosis 
and proliferation players AURKA/B, cyclin-dependent kinase 1 (CDK1), CDCA8 and INCENP; (B) whereas L1-cell adhesion molecule (L1-CAM) showed 
very strong interactions with neural cell adhesion molecule 1 (NCAM1), neuropilin-1 (NRP1), NCAN, contactin 2 (CNTN2), RANBP1 and epidermal growth 
factor receptor (EGFR) among others most of which are angiogenic markers.
Figure 4. The transcriptional knockdown of tumorigenic proteins significantly decreases protein expression. (A) Transient transfection with siRNA targeting 
L1-cell adhesion molecule (L1-CAM), high mobility group protein A1 (HMGA1), MYCN proto-oncogene, bHLH transcription factor (MYCN) and fatty-acid 
binding protein 5 (FABP5) abrogated their protein expression. (B) Densitometric analysis of multiple experimental repeats revealed a significant decrease in 
the expression of the said proteins compared to control siRNA-transfected cells. Experiments were run in triplicate and repeated >3 times. Results represent 
the means ± SEM; *P<0.05 and **P<0.001.
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no significant differences in the rate of the proliferation of 
IMR-32 cells at 0 and 24 h following the transcriptional KD of 
all the above-mentioned siRNA-targeted, tumorigenic proteins 
compared to the controls. However, there was a statistically 
significant reduction in the rate of cellular proliferation between 
the MYCN, L1-CAM, HMGA1 and FABP5 siRNA-transfected 
cells and the controls at 48, 72 and 96 h post-siRNA trans-
fection (Fig. 6A), implicating the role of these proteins in 
highly proliferative signaling pathways. The rate of the prolif-
eration of cells targeted with double-target siRNA transfection 
(MYCN + L1-CAM, MYCN + HMGA1, MYCN + FABP5, 
HMGA1 + L1-CAM, HMGA1 + FABP5 and FAB5 + L1-CAM) 
was also significantly decreased from 48 to 96 h post-transfec-
tion compared to the controls (Fig. 6B). Double-target siRNA 
transfection did not exert an additive effect on the rate of cell 
proliferation compared to the single-target siRNA-transfected 
cells (data not shown); thus, we speculate on the possible 
redundancy of the proliferative signaling pathways of these 
proteins. We then sought to examine the effects of FABP5 and 
HMGA1 transcriptional KD on the migration of IMR-32 cells, 
since L1-CAM (25) and MYCN (26,27) have been previously 
reported to affect neuroblastoma cell migration. Using the 
‘wound healing’ scratch assay (Fig. 6C) we observed a signifi-
cant decrease in the migratory capacity of the IMR-32 cells 
subjected to FABP5 or HMGA1 transcriptional KD at 24 h 
after ‘wound induction’ (Fig. 6D).
Transcriptional KD of FABP5 and MYCN induces the early 
apoptosis of IMR-32 cells. Lastly we wished to determine 
whether the transcriptional KD of the tumorigenic proteins 
would affect the rate of apoptosis of IMR-32 cells. The late 
apoptotic rate was not observed to differ significantly between 
the controls and siRNA-transfected cells of any target at 48 h 
following transcriptional KD (Fig. 7A). However, early apop-
tosis was significantly higher in the cells subjected to FABP5 
and MYCN transcriptional siRNA KD at 48 h, as determined 
by Annexin V/PI staining and FACS analysis (Fig. 7B). This 
was confirmed by immunofluorescence staining of the cells 
Figure 5. Transcriptional knockdown experiments reveal an interplay between tumorigenic proteins. (A) Western blot analysis revealed a concomitant sig-
nificant downregulation of MYCN proto-oncogene, bHLH transcription factor (MYCN) protein expression following the knockdown of L1-cell adhesion 
molecule (L1-CAM), high mobility group protein A1 (HMGA1) and fatty-acid binding protein 5 (FABP5) by siRNA in the IMR-32 cells compared to the con-
trols. (B) Conversely, MYCN knockdown by siRNA led to the concomitant significant downregulation of L1-CAM, HMGA1 and FABP5 protein expression, 
whereas (C) the combined knockdown of L1-CAM and FABP5 by siRNA led to the concomitant significant downregulation of HMGA1 protein expression. 
(D) MYCN, HMGA1 and FABP5 knockdown and the combined dual-target knockdown led to the concomitant downregulation of survivin protein expression. 
Non-adjacent bands of western blot experiments were re-aligned side by side to increase the clarity of the presented data and designated by a straight vertical 
line. Experiments were run in triplicate and repeated >3 times. Results represent the means ± SEM; *P<0.05 and **P<0.01.
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with Annexin V and PI (Fig. 7C). Perhaps a difference in the 
rate of late apoptosis would be observed had we conducted the 
apoptosis assay at 72 or 96 h post-transcriptional KD.
Discussion
Neuroblastoma is a devastating childhood cancer with a 
dismal prognosis if presented in the high-risk group at diag-
nosis. IMR-32 is a MYCN-amplified, highly malignant human 
neuroblastoma cell line. On the contrary, SK-N-SH, while a 
metastatic human neuroblastoma cell line derived from an 
epithelial origin (28), is non-MYCN-amplified (29), and hence, 
is considered less invasive than the IMR-32 cells and a good 
cell line to use in comparison to IMR-32. In addition to the 
well-established pathways known to affiliate with MYCN in 
tumorigenic processes, we sought to discover whether other 
tumorigenic proteins and/or pathways are also 'accomplices' of 
the main ‘culprit’ MYCN, in its pursuit of cancerous-progres-
sion, malignancy, anti-apoptosis and resistance to treatment in 
high-risk neuroblastoma.
Our preliminary analysis of the proteomic signa-
tures in the MYCN-amplified IMR-32 compared to the 
non-MYCN-amplified SK-N-SH cells revealed some note-
worthy, upregulated tumorigenic proteins in the IMR-32 
compared to the SK-N-SH cells. Enrichr mapped these proteins 
to highly cancerous pathways, including leptin signaling, 
AGE/RAGE signaling, AMPK signaling, Notch, SREBP and 
Rac1/Pak1/p38/MMP-2 signaling pathways, among others. 
The leptin signaling pathway is highly affiliated with cancer 
migration and invasion (30), whereas SREBP, AGE/RAGE, 
Notch, Rac and AMPK have all been implicated in the 
tumorigenesis of various nervous system cancers, as well as 
other solid tumors (19-24). IMR-32 cells represent a highly 
malignant, invasive, treatment-resistant form of neuroblastoma 
and the identification of these activated pathways within them 
has shed some light on the understanding of their malignant 
mechanisms.
Of the SILAC identified upregulated proteins, we selected 
to verify with western blot analysis, the protein expression of 
several that mapped to more than one activated tumorigenic 
pathways including, L1-CAM (mapped to upstream regulators 
APP and HIF-1α), HMGA1 (mapped to activated upstream 
regulators MYC, APP, E2F1, MYCN and SP1), FABP5 (mapped 
to activated upstream regulators MYC, SREBF2, SREBF1 and 
Figure 6. Transcriptional knockdown of tumorigenic proteins inhibits the proliferation and migration of IMR-32 cells. (A) Transient siRNA transfection and 
knockdown of MYCN proto-oncogene, bHLH transcription factor (MYCN), L1-cell adhesion molecule (L1-CAM), high mobility group protein A1 (HMGA1) 
and fatty-acid binding protein 5 (FABP5) protein expression led to a significant decrease in IMR-32 cell proliferation from 48-96 h compared to the controls, 
as determined using a WST-1 cell proliferation assay. (B) Double-siRNA targeted knockdown (MYCN + L1-CAM, MYCN + HMGA1, MYCN + FABP5, 
L1-CAM + HMGA1, L1-CAM + FABP5 and HMGA1 + FABP5) also led to significant decrease in the IMR-32 cellular proliferation rate from 48-96 h 
compared to the controls. (C) Representative images of ‘wound closure’ illustrate a reduction in the migratory capacity of the IMR-32 cells subjected to FABP5 
and HMGA1 siRNA knockdown. (D) The average area of ‘wound closure’ in multiple random fields, measured using AxioVision Systems software, revealed a 
statistically significant decrease in IMR-32 cell migration compared to the controls. Experiments were run in triplicate and repeated >3 times. Results represent 
the means ± SEM; *P<0.05.
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KITLG) and survivin or BIRC5 (mapped to activated upstream 
regulators IL3, MYCN and MYC) to determine their interac-
tion with MYCN in the IMR-32 cells. As shown in Table V, 
there is intriguing overlap between these upstream regulators 
in highly tumorigenic pathways including, pathways in cancer, 
transcriptional misregulation in cancer, PI3K/AKT, Ras, Rap1, 
TGF-β, HIF-1α, Wnt, insulin and mTOR signaling pathways. 
The mTOR pathway, one of the most potent signaling path-
ways involved in cellular proliferation and protein synthesis, is 
highly activated in MYCN-amplified cell lines (31). Moreover, 
when MYCN-amplified IMR-32 cells are treated with 
SU11657 (SUGEN), a selective multi-targeted tyrosine kinase 
inhibitor with antitumor and anti-angiogenic activity, their 
growth is significantly inhibited (32).
L1-CAM is a neural cell adhesion molecule L1 found to be 
expressed in numerous tumors, such as neuroblastomas (25), 
glioblastomas, melanomas, lymphomas, as well as breast, 
colon, small cell lung carcinomas and gastrointestinal stromal 
tumors (33,34). L1-CAM plays a significant role in tumor 
progression and metastatic behavior (35), and the expres-
sion profile analysis in multiple human tumors has identified 
L1-CAM as a molecular marker for differential diagnosis and 
targeted therapy (36). Of note, various studies have recently 
implicated L1-CAM in cancer stem-cell maintenance and 
propagation (37), the activation of DNA damage checkpoint 
response that confers resistant to radiation therapy (38) and 
cancer cell migration and malignancy (39) in glioblastoma and 
neuroblastoma (40). Moreover, the strong interactions between 
L1-CAM and EGFR, RANBP9 and NCAM1 (which affiliates 
with TGF-β) (41) and NRP1 (Fig. 3), may enhance IMR-32 cell 
invasion and metastasis via an angiogenesis-driven, migratory 
mechanism.
HMGA1 belongs to a large family of non-histone 
DNA-binding factors that play important architectural func-
tions in the organization of active chromatin (42). In addition 
to its role in physiologic processes, a deregulated HMGA1 
expression is described in most tumors of epithelial and mesen-
chymal origin, and is considered a hallmark of cancer (43). 
Particularly, higher levels of HMGA1 expression are associated 
with more malignant and metastatic phenotypes in epithelial 
cancers (44,45). Furthermore, HMGA1 regulation may be 
controlled by MYCN, which upregulates HMGA1 expression in 
neuroblastoma cells and in neuroblastoma-like tumors arising 
in MYCN transgenic mice. Moreover, HMGA1 has been shown 
to be a direct MYCN transcriptional target, suggesting that 
HMGA1 is a biologically relevant MYCN target gene (46).
Figure 7. Transcriptional knockdown of MYCN proto-oncogene, bHLH transcription factor (MYCN) and fatty-acid binding protein 5 (FABP5) induces cellular 
apoptosis of IMR-32 cells. (A) The rate of late cellular apoptosis between MYCN, L1-cell adhesion molecule (L1-CAM), high mobility group protein A1 (HMGA1) 
and FABP5 siRNA-transfected and control IMR-32 cells did not differ significantly at 48 h post-transfection as determined using an Annexin V/propidium iodide 
(PI) cell apoptosis assay and flow cytometry analysis. (B) The rate of early apoptosis in MYCN and FABP5 siRNA-transfected IMR-32 cells was significantly 
higher compared to controls (~27 and ~29% compared to ~17%, respectively) at 48 h post-transfection. (C) Fluorescence microscopy images of MYCN and FABP5 
siRNA-transfected cells stained with Annexin V (red) and PI (green) at 48 h post-transfection. Experiments were run in triplicates and repeated >3 times. Results 
represent the mean ± SEM.
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Table VI. Common tumorigenic pathways that MYC and our validated targets (BIRC5, HMGA1 and MYCN) mapped to.
   False
Pathway Pathway Observed discovery Matching proteins in
ID no. description gene count rate your network (labels)
GO.0051301 Cell division 6 0.000118 AURKA, AURKB, BIRC5, CDCA8, 
    CDK1, INCENP
GO.0007067 Mitotic nuclear division 5 0.000834 AURKB, BIRC5, CDCA8, CDK1, INCENP
GO.0007052 Mitotic spindle organization 3 0.0017 AURKA, AURKB, BIRC5
GO.0007059 Chromosome segregation 4 0.0017 AURKB, BIRC5, CDCA8, INCENP
GO.0043146 Spindle stabilization 2 0.00178 AURKA, AURKB
GO.0051225 Spindle assembly 3 0.00178 AURKA, AURKB, BIRC5
GO.0051302 Regulation of cell division 4 0.00382 AURKA, AURKB, BIRC5, MYC
GO.0007264 Small GTPase-mediated 5 0.00405 AURKB, BIRC5, CDCA8, CDK1, INCENP
 signal transduction
GO.0000910 Cytokinesis 3 0.00568 AURKB, BIRC5, INCENP
GO.0031145 Anaphase-promoting 3 0.00568 AURKA, AURKB, CDK1
 complex-dependent
 proteasomal ubiquitin-dependent
 protein catabolic process
GO.0010941 Regulation of cell death 6 0.00604 AURKA, AURKB, BIRC5, CDK1, 
    MYC, MYCN
GO.0006468 Protein phosphorylation 5 0.00685 AURKA, AURKB, BIRC5, CDK1, MYC
GO.0018105 Peptidyl-serine phosphorylation 3 0.00685 AURKA, AURKB, CDK1
GO.0034501 Protein localization to kinetochore 2 0.00685 AURKB, CDK1
GO.0035404 Histone-serine phosphorylation 2 0.00685 AURKA, AURKB
GO.0043066 Negative regulation of apoptotic process 5 0.00685 AURKA, AURKB, BIRC5, CDK1, MYC
GO.0051276 Chromosome organization 5 0.00736 AURKA, AURKB, CDCA8, HMGA1, MYC
GO.0006996 Organelle organization 7 0.00837 AURKB, BIRC5, CDCA8, CDK1, HMGA1, 
    INCENP, MYC
GO.0051781 Positive regulation of cell division 3 0.0103 AURKA, AURKB, BIRC5
GO.0035556 Intracellular signal transduction 6 0.0104 AURKB, BIRC5, CDCA8, CDK1, 
    INCENP, MYC
GO.0000086 G2/M transition of mitotic cell cycle 3 0.0122 AURKA, BIRC5, CDK1
GO.0022402 Cell cycle process 5 0.0122 AURKB, BIRC5, CDCA8, INCENP, MYC
GO.1902589 Single-organism organelle organization 6 0.0131 AURKB, BIRC5, CDCA8, CDK1, 
    HMGA1, INCENP
GO.0033043 Regulation of organelle organization 5 0.0134 AURKA, AURKB, BIRC5, HMGA1, MYC
GO.0090307 Mitotic spindle assembly 2 0.0136 AURKB, BIRC5
GO.0016568 Chromatin modification 4 0.0151 AURKA, AURKB, HMGA1, MYC
GO.0007049 Cell cycle 5 0.026 AURKB, BIRC5, CDCA8, INCENP, MYC
GO.0000075 Cell cycle checkpoint 3 0.0275 AURKB, BIRC5, CDK1
GO.0002053 Positive regulation of mesenchymal 2 0.0275 MYC, MYCN
 cell proliferation
GO.0007098 Centrosome cycle 2 0.0275 AURKA, CDK1
GO.0090068 Positive regulation of cell cycle process 3 0.0338 AURKA, AURKB, BIRC5
GO.0031577 Spindle checkpoint 2 0.0342 AURKB, BIRC5
GO.1903047 Mitotic cell cycle process 4 0.0372 AURKB, BIRC5, CDCA8, INCENP
GO.0030162 Regulation of proteolysis 4 0.0399 AURKA, BIRC5, CDK1, MYC
GO.0045840 Positive regulation of mitotic 2 0.0412 AURKA, BIRC5
 nuclear division
GO.0051303 Establishment of 2 0.0434 BIRC5, CDCA8
 chromosome localization
GO.0010639 Negative regulation of 3 0.0455 AURKA, AURKB, HMGA1
 organelle organization
As indicated, there was a strong interaction between BIRC5, HMGA1, MYC, MYCN and AURKA/B, CDK1 and CDCA8, all of which are 
highly affiliated with processes that drive cellular mitosis.
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STRING protein network analysis mapped HMGA1 to 
MYCN, SP1, E2F1 and SREBP1 [a transcription factor with 
an important role in lipid metabolism, previously found to 
be highly activated in malignancies (47)], SREBP-cleavage-
activating protein [SCAP which plays a role in trafficking 
SREBP1 from the ER to the Golgi apparatus and recently 
found to play a role in tumorigenesis (48)], insulin-like growth 
factor receptor 1 [IGF1R or INSR, a known driver of HIF-2α 
transcription via PI3K signaling (49)] and the gene KITLG 
[which codes for the ligand of the tyrosine-kinase receptor 
c-KIT, STAT1 and STAT4 and implicated in the suscepti-
bility of germ cell tumors such as testicular cancer (50,51)]. 
Furthermore, when we examined the networks linking 
only HMGA1, BIRC5 and MYCN, we identified very strong 
interactions with the highly tumorigenic AURKA/B, CDK1, 
CDCA8 (52) and INCENP (53). As strong cell proliferation 
players, we speculate that the IMR-32 cells overexpressing 
HMGA1 and MYCN have an enhanced mitotic and cell division 
capacity that favors tumor cell proliferation and the evasion of 
apoptosis. With HMGA1 being a common player in the above-
mentioned tumorigenic pathways, including HIF-1α, SREBP1, 
KITLG, AURKA/B, CDK1 and CDCA8, it is no surprise that 
MYCN-amplified IMR-32 cells or high-risk, MYCN-amplified 
neuroblastomas are highly malignant cancers.
FABP5 binds with a strong affinity to medium and long 
chain fatty acids, and translocates them into the nucleus 
where they stimulate their nuclear receptor PPARγ, which 
in turn stimulates other targets that lead to cancer expan-
sion and progression by enhanced angiogenesis and reduced 
apoptosis (54). Based on previous studies that have shown 
FABP5 upregulation in various tumors, its association with 
cancer malignancy and invasiveness (55) and the demon-
strated antitumor activity of the FABP5 chemical inhibitor 
SBFI26 (56), we decided to evaluate its role in the IMR-32 
neuroblastoma cells. We were particularly interested in FABP5 
as there are limited studies exploring its role in the aggressive, 
MYCN-amplified neuroblastoma cells. We were very intrigued 
by the observation that FABP5 mapped to the highly tumori-
genic MYC, SREBF1, SREBF2 and KITLG pathways further 
explaining the malignant nature of the IMR-32 cells.
Survivin or BIRC5 expression is strongly upregulated 
in aggressive, high-risk neuroblastoma compared to normal 
tissues, adult malignancies and non-malignant fetal adrenal 
neuroblasts (57). This upregulation correlates with an unfavor-
able prognosis in patients with neuroblastoma (58,59). BIRC5 
is a key regulator of mitosis and programmed cell death or 
apoptosis (60) and the smallest member of the family of 
inhibitor-of-apoptosis proteins (IAPs) (61,62). Thus, it is an 
ideal target for killing tumor cells specifically, while sparing 
healthy normal cells. We found BIRC5 to be highly affiliated 
with HMGA1, MYC and MYCN in the AURKA/B pathways, 
which may be critical interactions that fuel IMR-32 cell prolif-
eration and malignancy. In addition, STRING network analysis 
identified interactions between BIRC5 and IL3 [a stimulator 
of STATs and AKT pathways (63)] and HIF-1α [an angio-
genic driver in oxygen-deprived solid tumors (64) previously 
reported to protect neuroblastoma cells from hypoxia-induced 
apoptosis (63)]. The common denominator here is MYC, 
our validated targets affiliated either directly or indirectly 
(for example via MYCN) with MYC. Moreover, the intricate 
network between MYC, MYCN, AURKA/B and NCAM1, and 
our targets L1-CAM, HMGA1, BIRC5 and FABP5 links them 
to highly proliferative, angiogenic and metastatic tumorigenic 
pathways.
The transcriptional KD of all our proteins significantly 
inhibited the proliferation of IMR-32 cells and FABP5 
and MYCN KD inhibited early apoptosis, while FABP5 or 
HMGA1 KD inhibited cellular migration. The double-target 
transcriptional KD did not yield an additive effect on cell 
proliferation compared to single-target KD, implying that these 
proteins may signal through redundant proliferative pathways. 
In fact, HMGA1 and MYCN have been found to co-interact 
and HMGA1 was identified as a direct MYCN transcriptional 
regulator (46), which would explain the lack of an additive 
effect with combined, siRNA transcriptional KD of both 
targets, compared to single-target KD in our cells. Others have 
demonstrated the interplay between L1-CAM and EGFR in 
promoting cancer proliferation via ERK activation (65). ERK 
is a protein downstream of EGFR, platelet-derived growth 
factor receptor (PDGFR) and vascular endothelial growth 
factor (VEGFR) signaling, which are receptor tyrosine kinases 
that our validated proteins may signal through. For example, 
the FABP5-PPARγ-VEGF signaling transduction axis has 
been reported to be the pivotal tumorigenic pathway in pros-
tate cancer progression and malignancy (54). Furthermore, 
L1-CAM (66), HMGA1 (67) and MYCN (68), have all been 
reported to inhibit p53, thereby affecting cellular proliferation; 
in addition, L1-CAM (69), FABP5 (54) and MYCN all signal 
through the mTOR pathway via PI3K/AKT activation, and this 
may therefor explain the lack of an additive effect between 
single-target versus double-target KD on cell proliferation.
The fact that FABP5 and MYCN KD were able to induce 
early apoptosis of our IMR-32 cells at 48 h post-transfection 
implies that these proteins are crucial for cellular survival and 
thus early apoptotic rates were observed 48 h following their 
transcriptional KD. In support of our findings, Kawaguchi et al 
demonstrated the interaction of FABP5 with SP-1 and c-MYC 
(both determined by IPA to be upregulated in the IMR-32 
compared to SK-N-SH cells) to enhance cellular proliferation 
in cancer cells and the anti-proliferative effects of FABP5, 
SP1 or c-MYC silencing in prostate cancer cells (70). We 
have previously demonstrated the interplay between MYCN 
and L1-CAM in conferring the radioresistance of IMR-32 
cells (25) and L1-CAM has been previously reported to sustain 
ERK, FAK and PAK phosphorylation in apoptosis-resistant 
ovarian cancers, whereas its transcriptional KD sensitized 
ovarian carcinoma cells to apoptotic stimuli (71). We specu-
late that the interplay between L1-CAM, FABP5 and MYCN 
in this aggressive neuroblastoma cell line may be driving 
its malignant, apoptosis-resistant behavior. Of note, a recent 
study demonstrated the efficacy and safety of using the CE7 
monoclonal antibody to target L1-CAM in a (CAR)-redirected 
T-cell mediated immuno-therapy for children with neuroblas-
toma (72), which has shown promise in providing both in vitro 
and in vivo antitumor activity in primary, metastatic and 
recurrent neuroblastoma.
Our proteins validated by western blot analysis mapped to 
highly tumorigenic, activated upstream regulators which may 
help explain the aggressive nature of these malignant MYCN-
amplified cells. Seeing all these tumorigenic players highly 
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expressed in the IMR-32 neuroblastoma cells and of particular 
interest, their mapping to the activated upstream regulator, 
MYCN is quite intriguing and highlights the possible mecha-
nisms responsible for the aggressive, malignant nature of these 
cells. For instance, ISNR, SP1, SREBF1, IL3 and HIF-1α, 
which enhance tumor cell survival under stress-hypoxic 
conditions that favor proliferative processes and angiogenesis, 
may function as strong ‘accomplices’ of the main ‘culprit’, 
MYCN, in driving the malignant, tumorigenic behaviors of 
the IMR-32 cell line. In addition, AURKA/B with its strong 
interaction with HMGA1, BIRC5, MYC and MYCN, as well as 
the strong interaction between L1-CAM and the migratory and 
angiogenic players, including EGFR, RANBP1, NCAM1 and 
NRP1, may further be fueling the malignant propensity of the 
MYCN-amplified IMR-32 cells and the high-risk childhood 
neuroblastomas.
In conclusion, neuroblastoma that presents at diagnosis 
with high-risk disease is extremely difficult to cure and long-
term survival is rarely documented. It is of utmost importance 
to target the highly malignant, treatment evasive form of 
this disease with multi-modality therapeutic approaches. 
As demonstrated in the present study, the MYCN-amplified 
IMR-32 cells express highly tumorigenic proteins that belong 
to pathways that govern metastasis, invasion and migration of 
cancer cells; cancer stem cell propagation and maintenance; 
cancer angiogenesis, proliferation and evasion of apoptosis. In 
addition, our observation that the transcriptional KD of one 
target simultaneously downregulated another tumorigenic 
target indicates that an important network of interplay exists 
between highly tumorigenic proteins in these malignant 
cancer cells.
To the best of our knowledge, we are the first to illustrate 
the molecular crosstalk between these tumorigenic proteins 
and their affiliation with highly tumorigenic pathways in the 
MYCN-amplified IMR-32 neuroblastoma cells. Future studies 
are warranted to explore these interactions and to elucidate the 
exact mechanisms of this crosstalk, both at the cellular level 
and in pre-clinical models. Multi-modality targeted therapy 
against several non-redundant tumorigenic pathways may 
cripple this devastating disease and hinder malignant recur-
rence that almost always resists therapy, leading to mortality 
in affected children.
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